0000000000374356

AUTHOR

Emilie Grisot

showing 1 related works from this author

Mechanisms of Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa : Results of the GERPA Multicenter Study

2020

ABSTRACT Resistance mechanisms of Pseudomonas aeruginosa to ceftolozane/tazobactam (C/T) were assessed on a collection of 420 nonredundant strains nonsusceptible to ceftazidime (MIC > 8 μg/ml) and/or imipenem (>4 μg/ml), collected by 36 French hospital laboratories over a one-month period (the GERPA study). Rates of C/T resistance (MIC > 4/4 μg/ml) were equal to 10% in this population (42/420 strains), and 23.2% (26/112) among the isolates resistant to both ceftazidime and imipenem. A first group of 21 strains (50%) was found to harbor various extended-spectrum β-lactamases (1 OXA-14; 2 OXA-19; 1 OXA-35; 1 GES-9; and 3 PER-1), carbapenemases (2 GES-5; 1 IMP-8; and 8 VIM-2), or both (1 VIM-2…

TazobactamImipenemPopulationCeftazidimeMicrobial Sensitivity TestsBiologymedicine.disease_causeCeftazidimeTazobactambeta-LactamasesMicrobiology03 medical and health sciencesCloxacillinMechanisms of Resistance[CHIM.ANAL]Chemical Sciences/Analytical chemistrymedicineHumans[CHIM]Chemical SciencesPseudomonas InfectionsPharmacology (medical)[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyeducationComputingMilieux_MISCELLANEOUS030304 developmental biologyPharmacology0303 health scienceseducation.field_of_study030306 microbiologyPseudomonas aeruginosabiochemical phenomena metabolism and nutritionAnti-Bacterial AgentsCephalosporins3. Good healthInfectious DiseasesPseudomonas aeruginosaColistinCeftolozanemedicine.drug
researchProduct